Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)
Review of the Literature and Personal ExperienceMennel S. · Barbazetto I. · Meyer C.H. · Peter S. · Stur M.
aDepartment of Ophthalmology, Philipps University, Marburg, and bDepartment of Ophthalmology, University of Bonn, Bonn, Germany; cE.S. Harkness Eye Institute, Columbia Presbyterian Hospital, New York, N.Y., USA; dDepartment of Ophthalmology, Academic Hospital, Feldkirch, and eDepartment of Ophthalmology, Medical University of Vienna, Vienna, Austria
Photodynamic therapy (PDT) has become a well-established treatment for vascular forms of age-related macular degeneration (AMD). The implementation of evidence-based medicine principles into the treatment regimen of AMD seems to be immensly important, since AMD continues to be the most frequent cause of blindness among patients older than 65 years in industrialized countries. Numerous randomized prospective studies demonstrated high levels of evidence for the efficacy of various treatment approaches such as laser photocoagulation, PDT, subretinal surgery or novel anti-angiogenic drugs [Arch Ophthalmol 2006;124:597–599]. The high evidence shown by these studies supported the rationale to use PDT also in additional, less frequent, vasoproliferative diseases. Although these ‘case series’ and ‘individual case control studies’ have a low level of evidence, they give us important information for treatment decisions in these rare conditions. The goal of this survey is to review the current literature regarding PDT in vasoproliferative and exudative ocular diseases outside AMD. Many studies modified the treatment parameters of PDT to address the specific pathology of the underlying disease. Table 1 summarizes the diseases and treatment parameters that are described in this part 2, the entire table of this review is included in part 1 (www.karger.com/doi/10.1159/ 000101922).